Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Momelotinib Wins Japanese Approval for Myelofibrosis

June 24th 2024

The Ministry of Health, Labour, and Welfare in Japan has approved momelotinib for use in patients with myelofibrosis.

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis

June 21st 2024

This is safety and efficacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis

June 14th 2024

Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

June 14th 2024

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis

June 14th 2024

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Dr Watts on the Safety of the BET Inhibitor INCB057643 in Myelofibrosis

June 11th 2024

Justin M. Watts, MD, discusses the safety profile and tolerability of INCB057643 in patients with myelofibrosis.

Factors for JAK Inhibitor Selection in Myelofibrosis in the First Line and Beyond

June 9th 2024

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

Dr Sekeres on the FDA Approval of Imetelstat in Lower-Risk MDS With Anemia

June 7th 2024

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

FDA Approves Imetelstat for Low- to Intermediate-1–Risk MDS With Transfusion-Dependent Anemia

June 7th 2024

The FDA has approved imetelstat (Rytelo) for select patients with myelodysplastic syndrome and transfusion-dependent anemia.

Dr Kishtagari on JAK Inhibitor Selection for Myelofibrosis in the Community Setting

June 5th 2024

Ashwin Kishtagari, MD, discusses the selection process of JAK inhibitors for patients with myelofibrosis being treated in a community setting.

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

June 1st 2024

The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive patients with myelofibrosis.

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

May 31st 2024

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves

May 30th 2024

Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.

JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis

May 22nd 2024

Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.

Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis

May 21st 2024

Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.

Dr Gangat on JAK Inhibitor Selection in Treatment-Naive Myelofibrosis

May 17th 2024

Naseema Gangat, MBBS discusses the clinical utility of momelotinib and JAK inhibitor selection in treatment-naive myelofibrosis.

Dr Kishtagari on the Impact of Momelotinib on the Management of Anemic Myelofibrosis

May 16th 2024

Ashwin Kishtagari, MD, discusses how momelotinib addresses unmet needs in the management of anemic myelofibrosis following disease progression on ruxolitinib.

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

May 16th 2024

Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

Dr Klisovic on the Impact of Momelotinib on Myelofibrosis Management

May 9th 2024

Rebecca Klisovic, MD, discusses updates with JAK inhibitors, highlighting factors that inform JAK inhibitor selection in myelofibrosis.

NEXT PAGE
PREVIOUS PAGE